文献速递心脑血管急症重症综合管理与镇静镇痛

Andexanet 用于因子 Xa 抑制剂相关急性脑出血

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
PubMed 文献 · N Engl J Med · 2024-01-01
一句话结论对因子 Xa 抑制剂相关急性脑出血患者,andexanet 较常规治疗更有效控制血肿扩大,但血栓事件(包括缺血性卒中)增加。

ANNEXA-I 试验将 15 小时内发生急性脑出血且曾服用因子 Xa 抑制剂的患者按 1:1 随机分为 andexanet 组(263 例)和常规治疗组(267 例)。主要终点为止血有效性(12 小时血肿体积扩大≤35%、NIHSS 评分增加<7 分且 3-12 小时未接受抢救治疗),在 452 例患者的中期分析中评估:andexanet 组 224 例中 150 例(67.0%)达到,常规治疗组 228 例中 121 例(53.1%)达到(校正差异 13.4 个百分点;95%CI 4.6-22.2;P=0.003)。抗因子 Xa 活性中位降低幅度 andexanet 组 94.5% vs 常规治疗组 26.9%(P<0.001)。血栓事件 andexanet 组 10.3%(27/263) vs 常规治疗组 5.6%(15/267)(差异 4.6 个百分点;95%CI 0.1-9.2;P=0.048),缺血性卒中分别为 6.5%(17 例)和 1.5%(4 例)。两组改良 Rankin 量表评分或 30 天内死亡无显著差异。

要点

  • 止血有效性:andexanet 组 67.0%(150/224) vs 常规治疗组 53.1%(121/228),校正差异 13.4 个百分点(95%CI 4.6-22.2;P=0.003)。
  • 抗因子 Xa 活性中位降低:andexanet 组 94.5% vs 常规治疗组 26.9%(P<0.001)。
  • 血栓事件:andexanet 组 10.3%(27/263) vs 常规治疗组 5.6%(15/267),差异 4.6 个百分点(95%CI 0.1-9.2;P=0.048)。
  • 缺血性卒中:andexanet 组 17 例(6.5%) vs 常规治疗组 4 例(1.5%)。
  • 改良 Rankin 量表评分或 30 天内死亡两组无显著差异。

适用人群与场景

  • 在急性脑出血前 15 小时内服用过因子 Xa 抑制剂的患者。
  • 心房颤动是因子 Xa 抑制剂最常见的适应症。

诊断标准与关键阈值

  • 止血有效性定义:基线后 12 小时血肿体积扩大≤35%,且 12 小时美国国立卫生研究院卒中量表(NIHSS)评分增加<7 分(评分范围 0-42 分,分数越高神经功能缺损越重),且 3 至 12 小时期间未接受抢救治疗。

处置流程与药物剂量

  • andexanet 组接受 andexanet 治疗;常规治疗组接受常规治疗,其中 85.5% 接受了凝血酶原复合物浓缩物。

研究设计与关键结果

  • ANNEXA-I 为随机对照试验,共纳入 530 例患者,andexanet 组 263 例,常规治疗组 267 例;疗效在包含 452 例患者的中期分析中评估,安全性在全部 530 例入组患者中分析。
  • 主要终点止血有效性:andexanet 组 224 例中 150 例(67.0%)达到,常规治疗组 228 例中 121 例(53.1%)达到(校正差异 13.4 个百分点;95%CI 4.6-22.2;P=0.003)。
  • 抗因子 Xa 活性从基线至 1-2 小时最低值的中位降低幅度:andexanet 组 94.5%,常规治疗组 26.9%(P<0.001)。
  • 血栓事件:andexanet 组 263 例中 27 例(10.3%),常规治疗组 267 例中 15 例(5.6%)(差异 4.6 个百分点;95%CI 0.1-9.2;P=0.048);缺血性卒中分别发生于 17 例(6.5%)和 4 例(1.5%)。
  • 两组改良 Rankin 量表评分或 30 天内死亡无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(ANNEXA-I,ClinicalTrials.gov 注册号 NCT03661528)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对 15 小时内服用过因子 Xa 抑制剂的急性脑出血患者,andexanet 较常规治疗(85.5% 接受凝血酶原复合物浓缩物)更有效控制血肿扩大,但血栓事件(包括缺血性卒中)增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied.

METHODS: We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care. The primary end point was hemostatic efficacy, defined by expansion of the hematoma volume by 35% or less at 12 hours after baseline, an increase in the score on the National Institutes of Health Stroke Scale of less than 7 points (scores range from 0 to 42, with higher scores indicating worse neurologic deficit) at 12 hours, and no receipt of rescue therapy between 3 hours and 12 hours. Safety end points were thrombotic events and death.

RESULTS: A total of 263 patients were assigned to receive andexanet, and 267 to receive usual care. Efficacy was assessed in an interim analysis that included 452 patients, and safety was analyzed in all 530 enrolled patients. Atrial fibrillation was the most common indication for factor Xa inhibitors. Of the patients receiving usual care, 85.5% received prothrombin complex concentrate. Hemostatic efficacy was achieved in 150 of 224 patients (67.0%) receiving andexanet and in 121 of 228 (53.1%) receiving usual care (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 4.6 to 22.2; P = 0.003). The median reduction from baseline to the 1-to-2-hour nadir in anti-factor Xa activity was 94.5% with andexanet and 26.9% with usual care (P<0.001). Thrombotic events occurred in 27 of 263 patients (10.3%) receiving andexanet and in 15 of 267 (5.6%) receiving usual care (difference, 4.6 percentage points; 95% CI, 0.1 to 9.2; P = 0.048); ischemic stroke occurred in 17 patients (6.5%) and 4 patients (1.5%), respectively. There were no appreciable differences between the groups in the score on the modified Rankin scale or in death within 30 days.

CONCLUSIONS: Among patients with intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better control of hematoma expansion than usual care but was associated with thrombotic events, including ischemic stroke. (Funded by Alexion AstraZeneca Rare Disease and others; ANNEXA-I ClinicalTrials.gov number, NCT03661528.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med. 2024. PMID: 38749032. doi:10.1056/NEJMoa2313040

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。